We spoke to Dr Pavel Osmančik (Department of Arrhythmology, University Hospital Královské Vinohrady, Prague, Czech Republic) about the results from the PRAGUE-17 study and left atrial appendage closure, and the current strategies for preventing cardioembolic events in patients with atrial fibrillation.
Speaker’s Disclosures: Pavel Osmančik has nothing to declare in relation to this video interview.
Questions:
1. What are the current strategies for preventing cardioembolic events in patients with atrial fibrillation? (0:04)
2. The PRAGUE-17 study examined the efficacy of percutaneous left atrial appendage closure compared with novel anticoagulation agents; what are your observations at this point? (0:53)
3. Which patient populations do you consider are most likely to benefit from left atrial appendage closure? (2:47)
touchCARDIO.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.
Filmed in partnership with the Arrhythmia Alliance (A-A) at the European Society of Cardiology (ESC) Congress 2019 in Paris, France, September 2019.
